You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Boehringer Ingelheim
Harvard Business School
Baxter
McKesson

Last Updated: September 21, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for HGP0904

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug HGP0904?

HGP0904 is an investigational drug.

There have been 7 clinical trials for HGP0904. The most recent clinical trial was a Phase 3 trial, which was initiated on July 16th 2019.

The most common disease conditions in clinical trials are Hypertension, Dyslipidemias, and Erectile Dysfunction. The leading clinical trial sponsors are Hanmi Pharmaceutical Company Limited, Seoul National University Bundang Hospital, and [disabled in preview].

There are two US patents protecting this investigational drug and twenty-nine international patents.

Recent Clinical Trials for HGP0904
TitleSponsorPhase
A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and DyslipidemiaHanmi Pharmaceutical Company LimitedPhase 3
A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination and Co-Administration of HGP0904, HGP0608 and HCP1306 Tablets in Healthy Male Subjects.Hanmi Pharmaceutical Company LimitedPhase 1
A Study to Evaluate the Pharmacokinetic and Pharmacodynamic Interactions Between HGP0904, HGP0608, and HCP1306 in Healthy Male Subjects.Hanmi Pharmaceutical Company LimitedPhase 1

See all HGP0904 clinical trials

Clinical Trial Summary for HGP0904

Top disease conditions for HGP0904
Top clinical trial sponsors for HGP0904

See all HGP0904 clinical trials

US Patents for HGP0904

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
HGP0904   Start Trial Combination therapy Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   Start Trial
HGP0904   Start Trial Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA)   Start Trial
HGP0904   Start Trial Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators Reset Therapeutics, Inc. (South San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Boehringer Ingelheim
Harvard Business School
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.